One of largest drug makers. Portfolio of 260 products and local market share of 7%. Focuses on higher margin generics, about 88% of its drug portfolio. Remaining products manufactured under license from multinationals. Domestic market accounted for 79% of revenue in 9M08. Plans to expand projects by new factory in Algeria (EGP 1100 M). ISO 9001 and ISO 14001 certified.